---
title: "JINGXIN Pharmaceutical signed a patent licensing agreement related to the hydrochloride of carbidopa formulations and raw materials"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/252006673.md"
description: "JINGXIN Pharmaceutical has signed a patent licensing agreement with Gedeon Richter for the hydrochloride formulation and active pharmaceutical ingredient of cariprazine. According to the agreement, JINGXIN Pharmaceutical obtains exclusive rights to develop, manufacture, and commercialize the drug in mainland China. Hydrochloride cariprazine is primarily used for the treatment of schizophrenia and bipolar disorder. JINGXIN Pharmaceutical is required to pay milestone payments of up to €530,000 and pay Gedeon Richter a sales share based on sales revenue after the product is launched"
datetime: "2025-08-07T10:23:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252006673.md)
  - [en](https://longbridge.com/en/news/252006673.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252006673.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/252006673.md) | [English](https://longbridge.com/en/news/252006673.md)


# JINGXIN Pharmaceutical signed a patent licensing agreement related to the hydrochloride of carbidopa formulations and raw materials

According to the announcement from JINGXIN Pharmaceutical (002020.SZ), the company has signed a Patent License Agreement with Gedeon Richter. Under the agreement, Gedeon Richter will grant JINGXIN Pharmaceutical an exclusive license for a patent, allowing JINGXIN Pharmaceutical to develop, manufacture, and commercialize hydrochloride cariprazine formulations and active pharmaceutical ingredients (API) within the licensed area (mainland China).

The announcement indicates that hydrochloride cariprazine is an atypical antipsychotic drug that acts as a partial agonist of dopamine D2 and D3 receptors. It is primarily used for the treatment of adult schizophrenia, acute treatment of manic or mixed episodes associated with adult bipolar I disorder, treatment of depressive episodes associated with adult bipolar I disorder (bipolar depression), and as an adjunct treatment for major depressive disorder (MDD) in antidepressant treatment (ADT).

According to the agreement, upon meeting certain conditions, including obtaining regulatory approval, JINGXIN Pharmaceutical will pay Gedeon Richter a milestone payment not exceeding €530,000. Additionally, after the hydrochloride cariprazine product is launched and sold in the licensed area (mainland China), JINGXIN Pharmaceutical will pay Gedeon Richter a corresponding sales share based on the net sales of the product in the licensed area under different applicable conditions as stipulated in the agreement

### 相關股票

- [JINGXIN (002020.CN)](https://longbridge.com/zh-HK/quote/002020.CN.md)

## 相關資訊與研究

- [How to approach the market during the "fog of war"](https://longbridge.com/zh-HK/news/281686621.md)
- [3 stocks to sell before earnings season](https://longbridge.com/zh-HK/news/281618406.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-HK/news/281644038.md)
- [National minimum pay rises challenge businesses](https://longbridge.com/zh-HK/news/281388859.md)
- [Private Equity Sales Slump as AI, War Bring New Stress Fractures](https://longbridge.com/zh-HK/news/281467301.md)